Crossmark

ΔSUVmax adds prognostic value to early response assessment during the first-line treatment of classical Hodgkin lymphoma: a retrospective cohort study

Crossref DOI link: https://doi.org/10.1186/s40644-025-00904-x

Published Online: 2025-07-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Pinczés, László Imre

Tóthfalusi, Dávid

Dobó, Boglárka

Barna, Sándor

Farkas, Bence

Garai, Ildikó

Illés, Árpád

Miltényi, Zsófia
Funding

Funding for this research was provided by:

University of Debrecen
License Information

Text and Data Mining valid from 2025-07-01

Version of Record valid from 2025-07-01
More Information

Article History

Received: 18 December 2024

Accepted: 22 June 2025

First Online: 1 July 2025

Declarations

:

: The study protocol followed the ethical guidelines of the 1975 Declaration of Helsinki, and ethical approval was obtained from the institutional review board of University of Debrecen, Debrecen, Hungary (IRB number: 4881). Written informed consents were obtained from all patients prior to treatment.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below